Novo Nordisk (NVO) — The Rebrand Can't Hide the Prescription

GLP-1 Market Share Loss, a 40% Drawdown, and a Strategy Reset Six Days Before Capital Markets Day — Quick Take

📅 Sep 15, 2026 HealthcarePharmaGLP-1 / ObesityNASDAQ

Market Cap

$190B

Revenue (TTM)

DKK 309B

P/E (TTM)

~11x

Rev Growth

-4 to -12%

Why This Company Now

On Sep 14 the one genuine single-name corporate story in the daily financial flow was Novo Nordisk rebranding to "Novo" — a name change, a new culture framework ("The Novo Way"), and a CEO (Mike Doustdar) openly saying the drugmaker must "rethink" its obesity strategy. That lands six days before a Capital Markets Day (Sep 21, London) where the full strategic reset is due, and after a Sep 11 Morgan Stanley downgrade to Underweight with a DKK 250 target. Sector backdrop: Healthcare was the #2 sector in the most recent US VolumeSurge (8 names), with GLP-1-adjacent Moderna the #2 pick — the screener says money is rotating into healthcare while this franchise is being repriced. Not previously covered; market cap ~$190B, comfortably above the $15B floor.

Financial Snapshot

Year	Revenue (DKK b)	Rev Growth	Op Margin	Net Income (DKK b)
FY2022	177.0	+26%	42.3%	55.5
FY2023	232.3	+31%	44.2%	83.7
FY2024	290.4	+25%	41.6%	101.3
FY2025	309.1	+6%	41.3%	102.4
Q2 2026 (adj.)	—	+7% CER	—	adj. op profit 33.4

Reported in DKK. FY2025 sales +6% in DKK (+10% CER), with net profit up just 1% to DKK 102.4b as the operating margin slipped to 41.3%. Mix tells the story: Obesity care +26% to DKK 82.3b, Diabetes care flat at DKK 207.1b (Ozempic +6%, Rybelsus -5%, Victoza -45%). Q2 2026 adjusted sales +7% CER and adjusted operating profit +11% CER to DKK 33.4b, but reported operating profit fell 19% and EPS fell 20% after DKK 6.3b of pipeline write-offs. Full-year 2026 adjusted sales and adjusted operating profit are guided to decline 4-12% at CER (narrowed from 5-13%).

Bull vs Bear

✅ Bull Case

Valuation has de-rated to a value multiple. At ~11x trailing earnings and ~$190B market cap — versus an all-time high of $135.66 (Jun 2024) and a $46.77 close on Sep 2 — the market is pricing a declining, structurally challenged business, not the global leader in a market whose branded GLP-1 volumes grew 104%.
The oral Wegovy franchise is working. The pill passed 3 million prescriptions by June, with Q1 pill sales of DKK 2.26b nearly double analyst forecasts and management citing double-digit growth despite competition — an oral GLP-1 is the cheapest path to the mass obesity market.
Optionality is stacked into the next two quarters: the Sep 21 Capital Markets Day strategy reset, a US obesity decision for CagriSema around end-2026, and an international oral Wegovy rollout (UK, Germany) that is the main driver of consensus mid-case.

🔴 Bear Case

The share loss is real and widening. Novo held 38.8% of the obesity market in Q2 versus Eli Lilly's 60.9% (IQVIA, via Lilly's presentation), and global diabetes value share fell 3.6pts to 30.1%. Losing the category you invented is a thesis problem, not a marketing problem.
Price is being sacrificed to defend volume. Pre-announced 50% Wegovy and 35% Ozempic US price cuts effective January 2027, plus a 9,000-role restructuring, mean 2026 adjusted sales and profit are guided down 4-12% at CER. A rebrand and a culture deck do not fix gross-to-net.
Pipeline and sentiment risk are live. Three trials on an experimental cardiovascular drug were scrapped in July; Morgan Stanley cut to Underweight (DKK 250 target) on Sep 11 citing the semaglutide patent cliff and slower obesity growth; and the stock is down ~15% YTD.

Verdict

This is now a classic broken-compounder setup: a business still growing volume in a category with enormous runway, trading at a low-teens multiple because it is ceding share and cutting price to defend it. The Sep 21 Capital Markets Day is the whole ballgame for the near term — if management shows a credible oral-GLP-1-led path back to mid-single-digit growth and CagriSema delivers, ~11x looks too cheap; if it is a rebrand without numbers, the multiple is deserved and the drawdown continues. The rebrand is a signal, not a catalyst — the prescription data is the catalyst. Worth watching closely into Sep 21, not yet worth owning ahead of it.

Disclaimer: AI-generated quick take for informational purposes only. Not investment advice. Data from public filings and financial data providers.